Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study.

Villanueva V, Serratosa JM, Guillamón E, Garcés M, Giráldez BG, Toledo M, Salas-Puig J, López González FJ, Flores J, Rodríguez-Uranga J, Castillo A, Mauri JA, Camacho JL, López-Gomáriz E, Giner P, Torres N, Palau J, Molins A.

Epilepsy Res. 2014 Sep;108(7):1243-52. doi: 10.1016/j.eplepsyres.2014.04.014. Epub 2014 May 14.

PMID:
24908564
2.

Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: Case series.

Gómez-Ibáñez A, Serratosa JM, Guillamón E, Garcés M, Giráldez BG, Toledo M, Salas-Puig J, López-González FJ, Rodríguez-Uranga J, Castillo A, Mauri JA, Camacho JL, López-Gomáriz E, Giner P, Torres N, Palau J, Molins A, Villanueva V.

Seizure. 2017 May;48:53-56. doi: 10.1016/j.seizure.2017.04.003. Epub 2017 Apr 7.

PMID:
28419947
3.

Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study.

Correia FD, Freitas J, Magalhães R, Lopes J, Ramalheira J, Lopes-Lima J, Chaves J.

Epilepsy Res. 2014 Oct;108(8):1399-405. doi: 10.1016/j.eplepsyres.2014.06.017. Epub 2014 Jul 6.

PMID:
25060997
4.

Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.

Zaccara G, Giovannelli F, Maratea D, Fadda V, Verrotti A.

Seizure. 2013 Sep;22(7):528-36. doi: 10.1016/j.seizure.2013.03.016. Epub 2013 Apr 25. Review.

5.

Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results.

Massot A, Vivanco R, Principe A, Roquer J, Rocamora R.

Neurologia. 2014 Mar;29(2):94-101. doi: 10.1016/j.nrl.2013.02.013. Epub 2013 Apr 25. English, Spanish.

6.

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.

Elger C, Halász P, Maia J, Almeida L, Soares-da-Silva P; BIA-2093-301 Investigators Study Group.

Epilepsia. 2009 Mar;50(3):454-63. doi: 10.1111/j.1528-1167.2008.01946.x. Epub 2009 Feb 21.

7.

Practical guidance and considerations for transitioning patients from oxcarbazepine or carbamazepine to eslicarbazepine acetate--Expert opinion.

Peltola J, Holtkamp M, Rocamora R, Ryvlin P, Sieradzan K, Villanueva V.

Epilepsy Behav. 2015 Sep;50:46-9. doi: 10.1016/j.yebeh.2015.05.036. Epub 2015 Jun 24.

PMID:
26114438
8.

Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.

Sperling MR, Abou-Khalil B, Harvey J, Rogin JB, Biraben A, Galimberti CA, Kowacs PA, Hong SB, Cheng H, Blum D, Nunes T, Soares-da-Silva P; 304 Study Team.

Epilepsia. 2015 Feb;56(2):244-53. doi: 10.1111/epi.12894. Epub 2014 Dec 22.

9.

[Eslicarbazepine acetate in clinical practice. Efficacy and safety results].

Serrano-Castro PJ, Payán-Ortiz M, Cimadevilla JM, Quiroga-Subirana P, Fernández-Pérez J.

Rev Neurol. 2013 Mar 16;56(6):309-14. Spanish.

10.

Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures.

Perucca E, Elger C, Halász P, Falcão A, Almeida L, Soares-da-Silva P.

Epilepsy Res. 2011 Sep;96(1-2):132-9. doi: 10.1016/j.eplepsyres.2011.05.013. Epub 2011 Jun 15.

PMID:
21680153
11.

Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.

Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P.

Epilepsy Res. 2010 May;89(2-3):278-85. doi: 10.1016/j.eplepsyres.2010.01.014. Epub 2010 Mar 17.

PMID:
20299189
12.

Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study.

Hufnagel A, Ben-Menachem E, Gabbai AA, Falcão A, Almeida L, Soares-da-Silva P.

Epilepsy Res. 2013 Feb;103(2-3):262-9. doi: 10.1016/j.eplepsyres.2012.07.014. Epub 2012 Aug 4.

PMID:
22871333
13.

Real-world data on eslicarbazepine acetate as add-on to antiepileptic monotherapy.

Holtkamp M, McMurray R, Bagul M, Sousa R, Kockelmann E.

Acta Neurol Scand. 2016 Jul;134(1):76-82. doi: 10.1111/ane.12574. Epub 2016 Feb 24.

14.

[Anticonvulsant add-on therapy with Eslicarbazepine acetate : Results of the EPOS-study in adults in Germany].

Losch FP, Holtkamp M, McMurray R, Lendemans D, Kockelmann E.

Nervenarzt. 2016 Oct;87(10):1094-1099. German.

PMID:
27550387
15.

Overnight switching from oxcarbazepine to eslicarbazepine acetate: an observational study.

Schmid E, Kuchukhidze G, Kirschner M, Leitinger M, Höfler J, Rohracher A, Kalss G, Wendling AS, Steinhoff BJ, Trinka E.

Acta Neurol Scand. 2017 Apr;135(4):449-453. doi: 10.1111/ane.12645. Epub 2016 Jul 22.

PMID:
27444636
16.

Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies.

Gil-Nagel A, Elger C, Ben-Menachem E, Halász P, Lopes-Lima J, Gabbai AA, Nunes T, Falcão A, Almeida L, da-Silva PS.

Epilepsia. 2013 Jan;54(1):98-107. doi: 10.1111/j.1528-1167.2012.03605.x. Epub 2012 Aug 6.

17.

Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.

Shorvon SD, Trinka E, Steinhoff BJ, Holtkamp M, Villanueva V, Peltola J, Ben-Menachem E.

J Neurol. 2017 Mar;264(3):421-431. doi: 10.1007/s00415-016-8338-2. Epub 2017 Jan 18. Review.

18.

Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures.

Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-da-Silva P; BIA-2093-303 Investigators Study Group.

Acta Neurol Scand. 2009 Nov;120(5):281-7. doi: 10.1111/j.1600-0404.2009.01218.x.

PMID:
19832771
19.

Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study.

Jacobson MP, Pazdera L, Bhatia P, Grinnell T, Cheng H, Blum D; study 046 team.

BMC Neurol. 2015 Mar 28;15:46. doi: 10.1186/s12883-015-0305-5.

20.

Clinical utility of eslicarbazepine: current evidence.

Zaccara G, Giovannelli F, Cincotta M, Carelli A, Verrotti A.

Drug Des Devel Ther. 2015 Feb 10;9:781-9. doi: 10.2147/DDDT.S57409. eCollection 2015. Review.

Supplemental Content

Support Center